(MENAFN- GlobeNewsWire – Nasdaq) LOS ANGELES, Feb. 2, 2024 (GLOBE NEWSWIRE) — Frank R. Cruz reminds investors that elegance action lawsuits have been filed on behalf of shareholders of the following publicly traded companies. below to register a lead plaintiff application.
Investors who incur losses on their investments are encouraged to contact Frank R. Law Firms. Cross to discuss your legal rights in those elegance moves at 310-914-5007 or by email at. . . .
Dada Nexus Limited (NASDAQ: DADA) Class Period: May 11, 2023 to January 8, 2024 Main Applicant Deadline: March 11, 2024
The smart action complaint alleges that throughout the Class Period, the defendants made completely false and/or misleading statements, and failed to disclose adverse facts relating to the Company’s business, operations, and customers. Specifically, the defendants failed to disclose to investors that: (1) Dada’s revenues from online advertising, marketing services, and operating and aid prices were grossly exaggerated; (2) accordingly, Dada merits an independent review to determine the financial impact and extent of the suspicious practices that led to an overstatement of revenues and prices; and (3) as a result, the defendants’ positive statements relating to the Company’s business, operations, and customers were misleading and/or lacked a moderate basis at all times.
If you are a Dada Nexus shareholder who has suffered a loss, click to participate.
BioNTech SE (NASDAQ: BNTX) Appeal Period: March 30, 2022 to October 13, 2023 Main Applicant Deadline: March 12, 2024
The elegance action lawsuit alleges that during the Class Period, the defendants made grossly false and/or misleading statements, and failed to disclose adverse facts relating to the Company’s business, operations, and customers. Specifically, the defendants failed to disclose to investors that: (1) BioNTech exaggerated the demand of Comirnaty and/or its business customers; (2) the Company and/or Pfizer had accumulated excess inventories of raw fabrics for Comirnaty, as well as COVID-19 vaccine doses adapted to variants other than XBB. 1. 5 produced under threat; (3) as a result, BioNTech was under increased threat of major stock write-offs and other charges related to Comirnaty; and (4) as a result, defendants’ positive statements relating to the Company’s business, operations, and customers were misleading and/or lacked moderate basis at all applicable times.
If you are a BioNTech shareholder who has suffered a loss, click to participate.
Cummins Inc. (NYSE: CMI) Class Period: April 30, 2019 – December 21, 2023 Lead Plaintiff Deadline: March 15, 2024
The lawsuit filed in this lawsuit alleges that during the class period, Defendants made grossly false and/or misleading statements, and failed to disclose adverse facts relating to the Company’s business, operations, and customers. Specifically, the defendants failed to disclose to investors that: (1) contrary to their post-announcement assurances in April 2019 related to their compliance commitment, Cummins continued to produce engines equipped with illegal emission reduction devices. emissions from 2019 to 2023; (2) as a result, Cummins underestimated its legal and regulatory threat and overestimated its commitment to environmental protection; and (3) as a result, Defendants’ positive statements relating to the Company’s business, operations, and customers were misleading and/or lacked moderate basis at all applicable times.
If you are a Cummins shareholder and have suffered a loss, click to participate.
Follow us for updates on Twitter: twitter/FRC_LAW .
To be a member of these elegance actions, you do not need to take any action at this time; You may retain an attorney of your choice or take no action and remain an absentee elegance member. If you would like more information regarding those elegance actions, or if you have any questions about this announcement or your rights or interests with respect to those matters, please contact Frank R. Cruz, of the Frank R. Cruz Law Firm, 1999 Avenue. of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, via email at Array. . , or our online page at Array. If you apply by email, please provide your mailing address, telephone number, and the number of shares purchased.
This press release may be an advertisement for attorneys in certain jurisdictions based on applicable laws and moral standards.
Contacts
Frank R. Cruz Law Firm, Los AngelesFrank R. Cruz, 310-914-5007. . .
MENAFN02022024004107003653ID1107802836
Keywords
comment
Category
Date